Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TORCH Publication, DTC Campaign Breathe Life Into Advair In Q1

This article was originally published in The Pink Sheet Daily

Executive Summary

New prescription trends for the long-acting beta agonist bronchodilator trended up following publication of study results in the New England Journal of Medicine, DTC ads.

You may also be interested in...



FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD

Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.

FDA Says GlaxoSmithKline’s Advair 500/50 “Not Approvable” For COPD

Agency questions efficacy of COPD treatment over lower strength; GSK tells “The Pink Sheet” DAILY that head-to-head trials were not conducted.

GSK Submits Advair sNDA Based on TORCH Data

Company is seeking expanded labeling and approval of an increased dosage for treatment of COPD.

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel